Related Experiment Video
Updated: Dec 4, 2025
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
Anti-Inflammatory Effects of M-MSCs in DNCB-Induced Atopic Dermatitis Mice
Bokyeong Ryu1, Jieun Baek2, Hana Kim2
1Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
Abstract:
Atopic dermatitis (AD) is an inflammatory skin disease caused by an imbalance between Th1 and Th2 cells. AD patients suffer from pruritus, excessive dryness, red or inflamed skin, and complications such as sleep disturbances and depression. Although there are currently many AD treatments available there are insufficient data on their long-term stability and comparative effects. Moreover, they have limitations due to various side effects. Multipotent mesenchymal stem cells (M-MSCs) might have potential for next-generation AD therapies. MSCs are capable of immune function regulation and local inflammatory response inhibition. M-MSCs, derived from human embryonic stem cells (hESC), additionally have a stable supply. In L507 antibody array, M-MSCs generally showed similar tendencies to bone marrow-derived mesenchymal stem cells (BM-MSCs), although the immunoregulatory function of M-MSCs seemed to be superior to BM-MSCs. Based on the characteristics of M-MSCs on immunoregulatory functions, we tested a M-MSC conditioned media concentrate (MCMC) in mice with AD lesions on their dorsal skin. MCMC significantly decreased RNA expression levels of inflammatory cytokines in the mouse dorsal skin. It also suppressed serum IgE levels. In addition, significant histopathologic alleviation was identified. In conclusion, secretions of M-MSCs have the potential to effectively improve AD-related inflammatory lesions. M-MSCs showed potential for use in next-generation AD treatment.
Insights
Multipotent mesenchymal stem cell conditioned media concentrate (MCMC) effectively treats atopic dermatitis (AD) in mice. This novel therapy reduces inflammatory markers and improves skin lesions, offering a promising new treatment for AD.
Area of Science:
- Immunology
- Dermatology
- Regenerative Medicine
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by Th1/Th2 imbalance, leading to symptoms like pruritus and skin lesions.
- Current AD treatments have limitations, including insufficient long-term data, variable efficacy, and potential side effects.
- Multipotent mesenchymal stem cells (M-MSCs), derived from human embryonic stem cells (hESC), offer a stable supply and possess immunoregulatory properties.
Purpose of the Study:
- To investigate the therapeutic potential of M-MSC conditioned media concentrate (MCMC) for atopic dermatitis.
- To evaluate the immunomodulatory and anti-inflammatory effects of MCMC in a mouse model of AD.
Main Methods:
- M-MSC conditioned media concentrate (MCMC) was applied to mice with induced AD lesions.
- The study analyzed RNA expression of inflammatory cytokines in mouse dorsal skin.
- Serum IgE levels and histopathological changes were assessed to evaluate treatment efficacy.
Main Results:
- MCMC significantly reduced the RNA expression of key inflammatory cytokines in lesional skin.
- Treatment with MCMC led to a notable suppression of serum IgE levels.
- Histopathological examination revealed significant alleviation of AD-related skin damage.
Conclusions:
- Secretions from M-MSCs, concentrated as MCMC, demonstrate potent anti-inflammatory effects.
- MCMC shows significant potential for improving AD-related inflammatory lesions and offers a promising avenue for next-generation AD therapies.
